About Hindustan Laboratories Ltd.
Incorporated in 2017, Hindustan Laboratories Limited is an Indian pharmaceutical company primarily engaged in the large-scale manufacturing and supply of generic medicines to government institutions under a business-to-government (B2G) framework.
The company’s roducts are supplied mainly through procurement contracts for central government healthcare projects under the Ministry of Health and Family Welfare via Government of India agencies, as well as through state government agencies and bodies.
Hindustan Laboratories Limited supplied products across India to 27 states and Union Territories during the six months ended September 30, 2025, and to 27 states and Union Territories during Fiscal 2025. The company served 343 customers during the six months ended September 30, 2025, and 445, 474, and 439 customers in Fiscal 2025, Fiscal 2024, and Fiscal 2023, respectively.
The product portfolio covers a wide range of therapeutic segments addressing both acute and chronic healthcare requirements. These include anti-allergic, anti-diabetic, anti-infective, anti-malarial, antiparasitic, blood-related, cardiac, gastrointestinal, keratolytic, pain and analgesic, respiratory therapies, nutritional and mineral supplements, and vitamin supplements.
The company has formulation capabilities across multiple dosage forms, including tablets, capsules, powders, oral liquids, topical solutions, creams, ointments, combination blister packs, and topical powders. The product portfolio increased from 661 products as of March 31, 2023 to 871 products as of March 31, 2025, and further expanded to 948 products as of September 30, 2025.
The manufacturing facility (Unit 1) is located at Palghar, Maharashtra, approximately 100 km from Mumbai along National Highway 8, with connectivity by road, rail, and air. The facility is certified under ISO 9001:2015 for quality management systems.
An additional manufacturing unit (Unit 2) is located at the Palghar facility and is intended to support capacity expansion. Unit 2 is currently under commissioning, and commercial production has not yet commenced.
As of September 30, 2025, the workforce consisted of 284 employees and 332 contract laborers.
